ABILIFY Approved For Acute Treatment Of Bipolar I Disorder In Patients 10 To 17 Years Old

Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) has announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY® (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old).

More: continued here

Filed under: Bipolar on March 3rd, 2008